Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Depreciation and Depletion (2022 - 2025)

Barinthus Biotherapeutics' Depreciation and Depletion history spans 4 years, with the latest figure at $300000.0 for Q4 2025.

  • For Q4 2025, Depreciation and Depletion fell 50.0% year-over-year to $300000.0; the TTM value through Dec 2025 reached $2.8 million, up 7.69%, while the annual FY2025 figure was $2.9 million, 11.54% up from the prior year.
  • Depreciation and Depletion reached $300000.0 in Q4 2025 per BRNS's latest filing, up from $100000.0 in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $1.2 million in Q1 2025 to a low of $100000.0 in Q3 2025.
  • Average Depreciation and Depletion over 4 years is $550000.0, with a median of $550000.0 recorded in 2023.
  • Peak YoY movement for Depreciation and Depletion: skyrocketed 150.0% in 2023, then crashed 85.71% in 2025.
  • A 4-year view of Depreciation and Depletion shows it stood at $300000.0 in 2022, then surged by 133.33% to $700000.0 in 2023, then dropped by 14.29% to $600000.0 in 2024, then crashed by 50.0% to $300000.0 in 2025.
  • Per Business Quant, the three most recent readings for BRNS's Depreciation and Depletion are $300000.0 (Q4 2025), $100000.0 (Q3 2025), and $1.2 million (Q2 2025).